Fig. 1: Immune responses to intramuscular immunization with FEN-BSA are enhanced with dmLT adjuvant. | npj Vaccines

Fig. 1: Immune responses to intramuscular immunization with FEN-BSA are enhanced with dmLT adjuvant.

From: Fentanyl conjugate vaccine by injected or mucosal delivery with dmLT or LTA1 adjuvants implicates IgA in protection from drug challenge

Fig. 1

Groups of Balb/c mice (n = 4) were left naïve or immunized intramuscularly with 8 μg FEN-BSA ± 1 μg dmLT on weeks 0 and 4. Two-weeks later (week 6) serum, spleen, or bone-marrow were collected for antibody evaluations. a Schematic of immunization schedule identifying week of immunizations (IM) and sacrifice for blood, spleen, and bone-marrow sample collections (SAC). b Raw ELISA data for serum anti-BSA or anti-FEN IgG expressed as 405 nm optical density (OD) absorbance. For anti-FEN IgG, plates were coated with FEN-TT. c Compiled ELISA units (EU)/ml of indicated serum anti-BSA and anti-FEN IgG titers assessed by ELISAs graphed on a log2 scale. d Compiled EU/ml of indicated serum anti-FEN IgG1 or IgG2a. e Raw ELISA data for serum anti-FEN IgA and IgM. f Representative images for ASCs IgG/IgA ELISPOT results using splenocytes (Sp) or bone marrow (BM) cells and plates coated with FEN-TT. Blue spots indicate IgG ASCs and red spots IgA ASCs. g Compiled ASC per 106 cells from spleens or bone marrow. Bars at mean + s.e.m. with significance indicated as (***) for P ≤ 0.001 (*) for P ≤ 0.05 by one-way ANOVA with Bonferroni’s multiple comparisons test.

Back to article page